<PAGE>
Exhibit 99.1
For more information contact:
Sophia Twaddell
Fleishman-Hillard, Inc.
(312) 751-3738
[email protected]
----------------------
INSMED INCORPORATED ANNOUNCES PRELIMINARY DATA
FROM TWO CLINICAL TRIALS
RICHMOND, VA - (November 24, 2000) - Insmed Incorporated (Nasdaq: INSM) today
announced it has received preliminary data for two clinical trials.
Initial data from the SomatoKine(R) Type 2 diabetes trial demonstrated that
SomatoKine, whether delivered via continuous infusion or subcutaneous injection,
reduced insulin consumption and average daily blood glucose levels in Type 2
diabetics. SomatoKine has previously demonstrated similar effects in patients
with Type 1 diabetes. "We are pleased to extend the positive SomatoKine results
previously obtained from the treatment of patients with Type 1 diabetes to the
much larger population of Type 2 diabetics, and confirm the insulin-sensitizing
properties of SomatoKine," said Geoffrey Allan, Ph.D., President and CEO of
Insmed Incorporated.
In a separate trial, a preliminary intent-to-treat analysis showed that Type 2
diabetics treated with INS-1 in combination with sulfonylureas showed no
statistical significance from placebo. "The data is preliminary and inconsistent
with our previous trials for both Type 2 diabetes and polycystic ovarian
syndrome," commented Dr. Allan. "We intend to evaluate each patient in detail to
understand the significance of this data," he said.
About Insmed Incorporated
Insmed Incorporated is a biopharmaceutical company focused on the discovery and
development of pharmaceutical products for the treatment of metabolic diseases
and endocrine disorders associated with insulin resistance. Further information
is available at www.insmed.com.
# # #
Statements included within this press release, which are not historical in
nature, may constitute forward-looking statements for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include all statements regarding expected financial
position, results of operations, cash flows, dividends, financing plans,
business strategies, operating efficiencies or synergies, budgets, capital and
other expenditures, competitive positions, growth opportunities for existing or
proposed products or services, plans and objectives of management, demand for
new pharmaceutical products, market trends in the pharmaceutical business,
inflation and various economic and business trends. Such forward-looking
statements are subject to numerous risks and uncertainties, including risks that
product candidates may fail in the clinic or may not be successfully marketed,
the company may lack financial resources to complete development of product
candidates, competing products may be more successful, demand for new
pharmaceutical products may decrease, the biopharmaceutical industry may
experience negative market trends and other risks detailed from time to time in
the company's filings with the Securities and Exchange Commission. As a result
of these and other risks and uncertainties, actual results may differ materially
from those described in this press release.
